The increasing field of targeted treatment relies heavily on recombinant cytokine technology, and a thorough understanding of individual profiles is essential for fine-tuning experimental design and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 highlights significant differences in the